Results 91 to 100 of about 60,346 (233)

EBV+ and Kaposi’s Sarcoma Herpesvirus‐Associated Multicentric Castleman Disease in a Patient With HIV Infection: A Case Report

open access: yesCase Reports in Infectious Diseases, Volume 2026, Issue 1, 2026.
Multicentric Castleman disease is a rare proliferative disease of lymphoid tissue. It has rarely been reported in Asian countries, particularly in HIV‐positive patients. Here, we report a case of Kaposi’s sarcoma herpesvirus‐associated Multicentric Castleman disease (KSHV‐MCD).
Mai-Yin Huang   +6 more
wiley   +1 more source

ING116070: a study of the pharmacokinetics and antiviral activity of dolutegravir in cerebrospinal fluid in HIV-1-infected, antiretroviral therapy-naive subjects. [PDF]

open access: yes, 2014
BackgroundDolutegravir (DTG), a once-daily, human immunodeficiency virus type 1 (HIV-1) integrase inhibitor, was evaluated for distribution and antiviral activity in cerebrospinal fluid (CSF).MethodsING116070 is an ongoing, single-arm, open-label ...
Chen, Shuguang   +8 more
core   +3 more sources

Health Benefits and Therapeutic Potential of Quercetin

open access: yesJournal of Food Biochemistry, Volume 2026, Issue 1, 2026.
Quercetin, a polyphenolic compound prevalent in many fruits, vegetables, and other dietary sources, has attracted considerable interest due to its extensive health benefits. This review examines its diverse biological properties, particularly its antioxidant and anti‐inflammatory effects. The study integrates recent scientific findings to elucidate the
Mahendra Aryal, Kim Wei Chan
wiley   +1 more source

THE STUDY OF INFLUENCE OF PREPARATION «COMBIVIR» ON CARBOHYDRATE AND LIPID METABOLISM OF BLOOD SERUM

open access: yesСовременная наука и инновации, 2022
The purpose of this study was to evaluate the effect of the drug «Combivir» on indicators of carbohydrate metabolism and serum lipids in the systemic toxicity study conducted in conditions of chronic experiment.
Elena Olegovna Sergeeva   +2 more
doaj  

Management of Antiviral Resistance in Chronic Hepatitis B

open access: yesGut and Liver, 2017
The primary goal of therapy for chronic hepatitis B (CHB) is to prevent liver disease progression. Hepatitis B surface antigen (HBsAg) seroclearance or seroconversion is regarded as an optimal endpoint to discontinue treatment.
Young-Suk Lim
doaj   +1 more source

Reviewing the Drivers and Challenges in RFID Implementation in the Pharmaceutical Supply Chain [PDF]

open access: yes, 2009
Counterfeiting is a global phenomenon that poses a serious financial threat to the pharmaceutical industry and more importantly jeopardizes public safety and security.
Li, Suhong   +2 more
core   +2 more sources

Intermittent doravirine/lamivudine/tenofovir disoproxil fumarate (DOR/3TC/TDF) maintains a high level of viral suppression in virologically suppressed people living with HIV

open access: hybrid, 2023
Romain Palich   +7 more
openalex   +1 more source

Development and Characterization of Printlets of Lamivudine for Pediatric Patients Using Selective Laser Sintering

open access: yesPharmaceuticals
Background: Lamivudine is widely used alone or in combination with other anti-HIV drugs in the infant to adolescent age groups of pediatric populations. Compounding of medications is frequently used for pediatric patients.
Canberk Kayalar   +5 more
doaj   +1 more source

Tracking the source of the hepatitis B virus-specific CD8 T cells during lamivudine treatment [PDF]

open access: yes, 2003
Lamivudine treatment in chronic hepatitis B leads to the reconstitution of virus-specific T cells in the circulation, but it is not clear whether this is the preferential result of T cell efflux from the liver or lymph nodes.
Behboudi, S   +8 more
core   +1 more source

A one-year trial of lamivudine for chronic hepatitis B [PDF]

open access: yes, 1998
Background and Methods: In preliminary trials, lamivudine, an oral nucleoside analogue, has shown promise for the treatment of chronic hepatitis B. We conducted a one-year double-blind trial of lamivudine in 358 Chinese patients with chronic hepatitis B.
Barber, J   +11 more
core   +1 more source

Home - About - Disclaimer - Privacy